Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Roles at http://pharmaceuticalintelligence.com

Research Category OWNER:

Prabodh Kumar Kandala

Personal BIO

prabodh.kandala@gmail.com

I am an experienced biomedical scientist with substantial experience in preclinical research with a focus on target identification, characterization and validation.

I am very enthusiastic to use my training and research experience in identifying novel targets and strategies for prevention or treatment of cancer and other diseases through elucidating signal transduction pathways.

I have a sound knowledge in cancer biology and pharmacology. I have experience with wide variety of cell cultures, microbiology techniques. I am adept at handling wide variety of in vitro techniques. I am equally good at working with animals. I have a wide horizon of techniques. Importantly, I am willing to learn new things.

Specialties

Signal transduction, Mammalian cell culture, Cytotoxicity assays, flowcytometry, transient and stable transfections, Plasmid extraction, DNA, RNA and protein isolation, PCR, gel electrophoresis, Immunoprecipitation, Metastasis, angiogenesis, anoikis, autophagy assays. In-vivo efficacy of drugs in tumor models, tumor implantation in mice (xenograft and orthotopic), treatment (subcutaneous, intraperitoneal and topical route), tail vein injections, tissue and blood collection

PRABODH K. KANDALA, PhD

PROFESSIONAL EXPERIENCE

 

Research Assistant

Texas Tech University Health Sciences Center (2007-2012)

 Field of study is translational research and major focus is on chemoprevention of various cancers by elucidating signal transduction pathways that get altered in response to various anti-cancer agents.

Teaching Assistant in Drug Delivery Systems

Texas Tech University Health Sciences Center (2007-2009)

Mentored Pharm.D students on laboratory practices of various pharmaceutical formulations.

Teaching Assistant in Case Studies

Texas Tech University Health Sciences Center (2009-current)

Guided Pharm.D students about pharmacodynamics and ADME pathways of several drugs used to treat various diseases.

 

EDUCATIONAL QUALIFICATION

 

Doctor of Philosophy in Biomedical Sciences

School of Pharmacy, Texas Tech University Health Sciences Center (2007-2012 )

GPA: 3.7

Bachelor of Pharmaceutical Sciences

Osmania University (2003-07)

GPA: 4.0

 

Ph.D Thesis focus

1.         Pre clinical drug discovery and target identification focused on various signal transduction pathways.

2.         Apoptosis, angiogenesis, invasion, cell cycle, autophagy and anoikis.

3.         Evaluation of anti-cancer drugs for their effects on xenograft and orthotopic in vivo models.

Experimental Techniques and Research Experience

Cancer cell models: Ovarian, pancreatic, breast, melanoma, lung, colon and prostate cancers.

Molecular biology: Mammalian cell culture, Cytotoxicity assays, cell cycle, apoptosis, autophagy, anoikis assays, survival studies, Transient transfection studies, Plasmid extraction, DNA and RNA extraction, Protein extraction, Stable transfection, Polymerase chain reaction, siRNA transfection, Agarose gel electrophoresis, Western blotting, Aortic ring assay, Invasion assay, Wound healing assay, Immunoprecipitation, Kinase activities, ROS assays.

 

Pharmacological studies (in-vivo): In-vivo efficacy of various anti-cancer drugs in tumor models, IVIS Caliper Life Sciences in-vivo imager, tumor implantation in mice, treatment (subcutaneous, intraperitoneal and topical route), tail vein injections.

 

Analytical techniques: UV-Vis spectroscopy, Drug distribution studies in tumors and tissues, Flowcytometry (Apoptosis, cell cycle analysis, mitochondrial membrane potential, autophagy detection, calcium measurements, detection of ROS), UV spectrophotometer, Fluorimetry.

Toxicological studies (in-vivo): Tissue collection (lung, liver and kidney specimens), ALT, AST.

Microscopy: Light microscopy, Immunohistochemistry, Immunofluorescence, Immunocytochemistry.

Computer Skills

  Languages: SAS (Statistical Analysis Software), C/C ++

  Software: Imaging and scanning by using Photoshop, Graph pad Prism, NIH Image J software, ChemDraw.

  Well versed in using MS Word, Excel and Power Point.

Honors and Awards

 

• GSBS Outstanding Graduate Student Award- 2012
• GSBS Dean’s Scholar award 2009-2012.
• Accuri flowcytometers AACR travel scholarship award 2011.
• Mary Lou Clements Scholarship 2011.
• TTUHSC Research Days-Best presentation award – 2011.
• Mary Lou Clements Scholarship 2010.
• Outstanding GSAA student award 2010.
• TTUHSC Research Days-Best presentation award – 2010.
• GSAA travel award-2010.
• “Young Researcher Award” at the “International Symposium on Cancer Chemorprevention and Translational Research” at School of Life Sciences, Jawaharlal Nehru University, New Delhi, India in 2009.
• GSAA travel award-2011.

 

PEER REVIEWED PUBLICATIONS

 

Accepted manuscripts:

• Kandala PK and Srivastava SK. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting STAT-3. BMC Medicine 2012, 10:9: 1-18.
• Kandala PK and Srivastava SK. Blocking EGFR activation suppresses ovarian tumor growth in vitro and in vivo. J. Pharm and Exp Ther. 2012, 341:1-9.
• Kandala PK, Srivastava SK. Activation of checkpoint kinase 2 by 3,3′-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells. Mol Pharmacol. 2010 Aug;78(2):297-309.
• Batra S, Sahu RP, Kandala PK, Srivastava SK. Benzyl Isothiocyanate-Mediated Inhibition of Histone Deacetylase Leads to NF-KB Turnoff in Human Pancreatic Carcinoma Cells.Mol Pharmacol. 2010 Aug;78(2):297-309.
• Sahu RP, Batra S, Kandala PK, Brown TL, Srivastava SK. The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemother Pharmacol. 2010 Sep 17.
• Vad NM, Kandala PK, Srivastava SK, Moridani MY. Structure-toxicity relationship of phenolic analogs as anti-melanoma agents: An enzyme directed prodrug approach. Chemico-Biological Interactions. 2010 Feb 12;183(3):462-71. Epub 2009 Nov 26.

Manuscripts under processing:

 

• Kandala PK and Srivastava SK (2012). Gli1 suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo. (J Biol Chem. – Under revision) 

• Kandala PK and Srivastava SK (2012). Diindolylmethane induces autophagy by activating ER stress and AMPK (Oncotarget – Under revision)

• Loganathan SK^*, Kandala PK^*, Gupta P and Srivastava SK (2012). Inhibition of EGFR-Akt axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model. (PLoS ONE – Under revision) 

• Kandala PK and Srivastava SK (2012). JAK2 is a target of diindolylmethane in reducing the survival of ovarian cancer. (Drug discoveries and therapeutics – Under review).

Manuscripts under preparation:

 

•  Ravi P. Sahu, Prabodh K. Kandala, Srinivas Reddy Boreddy and Sanjay K. Srivastava (2012). Benzyl Isothiocyanate disrupts JAK3-STAT3-SOCS3 axis in pancreatic cancer cells (Under preparation).

 

•  Srinivas Reddy Boreddy, Prabodh K. Kandala and Sanjay K. Srivastava (2012). Critical role of autophagy proteins Beclin1 and LC3B in deguelin-induced apoptosis in pancreatic tumor cells in vitro and in vivo (Under preparation).

 

Published Abstracts & Poster Presentations

 

Published Abstracts

 

• Prabodh K. Kandala and Sanjay K. Srivastava. Activation of Chk2 by BR-DIM is required for causing G2/M arrest in Human ovarian cancer cells.  Proc. Am. Assos. Can. Res. Vol 50, 2009. 
• Prabodh K. Kandala and Sanjay K. Srivastava. STAT-3: a novel target of Diindolylmethane in ovarian cancer cells. Proc. Am. Assos. Can. Res. Vol 51, 2010
• Prabodh K. Kandala, Kartick C. Pramanik, Srinivas R. Boreddy and Sanjay K. Srivastava. 3,3’-diindolylmethane (DIM) induced apoptosis in ovarian tumors is mediated by inhibition of EGFR-ERK pathway. Proc. Am. Assos. Can. Res. Vol 51, 2010.
• Srinivas R. Boreddy, Kartick C. Pramanik, Prabodh K. Kandala and Sanjay K. Srivastava. Benzyl Isothiocynate suppresses pancreatic cancer invasion and angiogenesis by inhibiting PI3K/AKT and MMP2. Proc. Am. Assos. Can. Res. Vol 51, 2010.
• Kartick C. Pramanik, Srinivas R. Boreddy, Prabodh K. Kandala and Sanjay K. Srivastava. Involvement of mitochondrial respiratory chain in capsaicin mediated ROS generation in pancreatic cancer cells. Proc. Am. Assos. Can. Res. Vol 51, 2010
• Prabodh K. Kandala and Sanjay K. Srivastava (2011). Diindolylmethane potentiates the effect of cisplatin in ovarian cancer by inhibiting STAT-3 and VEGF. Proc. Am. Assos. Can. Res. Vol 52, 2011.
• Prabodh K. Kandala and Sanjay K. Srivastava (2011). Diindolylmethane induces ER stress mediated autophagy in ovarian cancer cells. Proc. Am. Assos. Can. Res. Vol 52, 2011.
• Srinivas Reddy Boreddy, Prabodh K. Kandala, Kartick C. Pramanik, Parul Gupta and Sanjay K. Srivastava (2012). Critical role of autophagy proteins Beclin1 and LC3B in deguelin-induced apoptosis in pancreatic tumor cells in vitro and in vivo: A new paradigm. Proc. Am. Assos. Can. Res. Vol 53, 2012.
• Prabodh K. Kandala and Sanjay K. Srivastava (2012). DIM regulates anoikis through sonic hedgehog in ovarian cancer cells. Proc. Am. Assos. Can. Res. Vol 53, 2012.
• Prabodh K. Kandala and Sanjay K. Srivastava (2012). Blocking Janus activated kinase-2 activation by DIM suppresses ovarian tumor growth in vitro and in vivo. Proc. Am. Assos. Can. Res. Vol 53, 2012.
• Srinivas Reddy Boreddy, Prabodh K. Kandala, Parul Gupta and Sanjay K. Srivastava (2012). HDAC inhibition reverses EMT through modulation of ZEB1. Proc. Am. Assos. Can. Res. Vol 53, 2012.

Poster presentations

• Ravi P. Sahu, Prabodh K. Kandala*, Michael W. Epperly and Sanjay K. Srivastava at Research Week, TTUHSC, Lubbock. March 2008.
• 3,3′-Diindolylmethane, a dietary agent causes G2/M arrest by activating CHK2 in human ovarian cancer cells. Prabodh K. Kandala and Sanjay K. Srivastava.at Research Days , TTUHSC, Amarillo June 2008.
• Activation of Chk2 by BR-DIM is required for causing G2/M arrest in Human ovarian cancer cells. Prabodh K. Kandala and Sanjay K. Srivastava. TTUHSC Student Research Week, Lubbock, TX, 2009.
• Activation of Chk2 by BR-DIM is required for causing G2/M arrest in Human ovarian cancer cells. Prabodh K. Kandala and Sanjay K. Srivastava. AACR, Denver, CO. 4/2009.
• Activation of Chk2 by BR-DIM is required for causing G2/M arrest in Human ovarian cancer cells. Prabodh K. Kandala and Sanjay K. Srivastava. Research days, TTUHSC, Amarillo. June 2009.
• Embelin induces apoptosis in pancreatic cancer cells by inhibiting ERK survival pathway. Brandon T. Cooper, Prabodh K. Kandala and Sanjay K. Srivastava. ABRI Summer Intern Symposium, TTUHSC, Amarillo. July 2009.
• BITC suppresses the growth of kidney cancer cells by activating ERK and inhibiting STAT-3. Faiz Hussain, Prabodh K. Kandala and Sanjay K. Srivastava. WHRI Summer Intern Symposium, TTUHSC, Amarillo. July 2009.
• Chemotherapeutic Effects of Diindolylmethane against Ovarian Cancer. Oral Presentation given at International Symposium on Cancer Chemoprevention and Translational Research, New Delhi, India, 12/21/09.
• Prabodh K. Kandala and Sanjay K. Srivastava. Stat-3: A novel target of Diindolylmethane in Ovarian cancer. TTUHSC Student Research Week, Lubbock. 3/2010.
• Prabodh K. Kandala and Sanjay K. Srivastava. STAT-3: a novel target of Diindolylmethane in ovarian cancer cells. AACR, Washington DC. April 2010.
• Prabodh K. Kandala, Kartick C. Pramanik, Srinivas R. Boreddy and Sanjay K. Srivastava. 2. 3,3’-diindolylmethane (DIM) induced apoptosis in ovarian tumors is mediated by inhibition of EGFR-ERK pathway. AACR, Washington DC. April 2010. 
• Prabodh K. Kandala, Kartick C. Pramanik, Srinivas Reddy Boreddy and Sanjay K. Srivastava. 3,3′-Diindolylmethane (DIM)-Induced Apoptosis in Ovarian Tumors is Mediated by Inhibition of EGFR-ERK Pathway. Research Days, TTUHSC SOP Amarillo. 6/10.
• Prabodh K. Kandala and Sanjay K. Srivastava. STAT-3: a novel target of Diindolylmethane in ovarian cancer cells. Research Days, TTUHSC SOP Amarillo. 6/10.
• Prabodh K. Kandala and Sanjay K. Srivastava. Diindolylmethane suppresses ovarian cancer and potentiates the effect of cisplatin in tumor mouse model by targeting STAT3. Annual GSBS Graduate Student & Mentor Retreat, Lubbock, TX. 1/11.
• Prabodh K. Kandala, Stephen E. Wright and Sanjay K. Srivastava. Diindolylmethane potentiates the effects of cisplatin in ovarian cancer by inhibiting STAT-3 and VEGF. Student Research Week, TTUHSC Lubbock. 3/11.
• Prabodh K. Kandala and Sanjay K. Srivastava. Diindolylmethane (DIM) induces ER stress mediated autophagy in ovarian cancer cells. Student Research Week, TTUHSC Lubbock. 3/11.
• Prabodh K. Kandala, Stephen E. Wright and Sanjay K. Srivastava. “Diindolylmethane potentiates the effects of cisplatin in ovarian cancer by inhibiting STAT-3 and VEGF”. AACR, Orlando. 4/11.
• Prabodh K. Kandala and Sanjay K. Srivastava. “Diindolylmethane (DIM) induces ER stress mediated autophagy in ovarian cancer cells”. AACR, Orlando. 4/11.
• Prabodh K. Kandala, Stephen E. Wright and Sanjay K. Srivastava. “Diindolylmethane potentiates the effects of cisplatin in ovarian cancer by inhibiting STAT-3 and VEGF”. TTUHSC 2011 Annual Cancer Symposium, Amarillo. 4/11.
• Prabodh K. Kandala and Sanjay K. Srivastava. “Diindolylmethane (DIM) induces ER stress mediated autophagy in ovarian cancer cells”. TTUHSC 2011 Annual Cancer Symposium, Amarillo. 4/11.
• Prabodh K. Kandala, Stephen E. Wright and Sanjay K. Srivastava. “Diindolylmethane potentiates the effects of cisplatin in ovarian cancer by inhibiting STAT-3 and VEGF”. Tenth Annual Research Days, Amarillo. 6/11.
• Prabodh K. Kandala and Sanjay K. Srivastava. “Diindolylmethane (DIM) induces ER stress mediated autophagy in ovarian cancer cells”. Tenth Annual Research Days, Amarillo. 6/11.
• Prabodh K. Kandala and Sanjay K. Srivastava. Diindolylmethane induces macroautophagy by regulating ER stress and AMPK. AAPS, Wash DC. 10/11.
• Prabodh Kumar Kandala and Sanjay Srivastava. “Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling Glucose regulatory protein 78 and AMPK”. Annual GSBS TTU Student Recruitment Event, Lubbock. 1/17/12.

Leadership

• Graduate Students Association at Amarillo (GSAA). Vice-President 2009-10
• American Association of Pharmaceutical Scientists, Amarillo Chapter. Secretary, 2010-11.
• American Association of Pharmaceutical Scientists, Amarillo Chapter. Chair-elect, 2011-12

Community Service

•  Juvenile Diabetes Research Foundation walk participant (2008-11)
• March of Dimes walk participant (2007-11).
• American Heart Association walk participant (2007-11).
• American Heart Association Walk T-shirt fundraiser (2009).
• Volunteered Plains Foodbank blood drive (2008-11).
• Volunteer at Hispanic foundation, mentored a session on how to quit smoking (2009).
• Donorschoose.org. Monetary help that will support studies of underprivileged students (2010-current). 

Affiliations and Memberships

 

• American Association of Cancer Research (2008-current).
• American Association of Pharmaceutical Scientists (2007-current).
• The American Association of Advancement in Science (2008-current).
• National Association of Science Writers (2009-2011).
• Graduate Student Association at Amarillo (2007-current).
• The Global Leaders (2012-current).